YAP1-MAML2 fusion in a pediatric NF2-wildtype intraparenchymal brainstem schwannoma.

TitleYAP1-MAML2 fusion in a pediatric NF2-wildtype intraparenchymal brainstem schwannoma.
Publication TypeJournal Article
Year of Publication2022
AuthorsKarajannis MA, Li BK, Souweidane MM, Liechty B, Yao J, Benhamida JK, Bale TA, Rosenblum MK
JournalActa Neuropathol Commun
Volume10
Issue1
Pagination117
Date Published2022 Aug 19
ISSN2051-5960
KeywordsBrain Stem, Child, Child, Preschool, Female, Gene Fusion, Humans, Meningeal Neoplasms, Meningioma, Neurilemmoma, Neurofibromatosis 2, Trans-Activators, Transcription Factors, YAP-Signaling Proteins
Abstract

Biallelic inactivation of NF2 represents the primary or sole oncogenic driver event in the vast majority of schwannomas. We report on a four-year-old female who underwent subtotal resection of a right medullary intraparenchymal schwannoma. RNA sequencing revealed an in-frame fusion between exon 5 of YAP1 and exon 2 of MAML2. YAP1-MAML2 fusions have previously been reported in a variety of tumor types, but not schwannomas. Our report expands the spectrum of oncogenic YAP1 gene fusions an alternative to NF2 inactivation to include sporadic schwannoma, analogous to what has recently been described in NF2-wildtype pediatric meningiomas. Appropriate somatic and germline molecular testing should be undertaken in all young patients with solitary schwannoma and meningioma given the high prevalence of an underlying tumor predisposition syndrome. In such patients, the identification of a somatic non-NF2 driver alteration such as this newly described YAP1 fusion, can help ascertain the diagnosis of a sporadic schwannoma.

DOI10.1186/s40478-022-01423-7
Alternate JournalActa Neuropathol Commun
PubMed ID35986430
PubMed Central IDPMC9392329
Grant ListP30 CA008748 / CA / NCI NIH HHS / United States
Related Faculty: 
Benjamin L. Liechty, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700